Achillion Pharmaceuticals

Marktübertreibungen

Der Cashbestand von 283 Mio. $ ist derzeit höher als die MK von 270 Mio. $.

www.fool.com/investing/2018/12/18/...s-cratering-again-t.aspx

Lead candidate ACH-4771 wird nicht in PNH-Monotherapie fortgeführt

www.fool.com/investing/2018/12/19/...ls-sank-again-today.aspx

MK 227 Mio. $

Achillion meldet Zahlen für 2018

• keine Umsätze
  
• Verlust 70 Mio. $
  
  • Q4/18 Verlust ~17 Mio. $
    
• bei ~20 Mio. $ Cashburn pro Quartal --> Cash-Reichweite ca. 13 Quartale
  
• Cash 271 Mio. $
  
• MK 369 Mio. $
  

"The company expects net cash usage for 2019 will be approximately $80 million based on current operating plans, anticipated timelines and the estimated costs of clinical trials and product development programs."

ir.achillion.com/news-releases/...and-full-year-2018-financial

Phase 2 ACHN-4471 Studie (C3G)

ir.achillion.com/news-releases/...-milestone-phase-2-trials-c3

positive Phase1 ACH-5228 Studiendaten

www.fool.com/investing/2019/07/22/...-stock-jumped-today.aspx

Danicopan erhält von der FDA den Status "Breakthrough Therapy designation"

www.thestreet.com/investing/...g-breakthrough-status-15103722

www.fool.com/investing/2019/09/25/...tock-is-jumping-tod.aspx

endpts.com/...nds-surer-footing-with-fda-breakthrough-status/

Alexion plant Übernahme von Achillion in einem 930 Mio. $ Deal

• Alexion bietet 6,30$
  
  • 2$ an potenziellen Zahlungen wenn klinische/regulatorische Meilensteine erreicht werden
    
    • 1$ wenn die FDA danicopan zulässt
      
    • 1$ wenn ACH-5228 in die Phase3 Studie geht
      
• 73% Premium auf den letzten Handelspreis vom Dienstag
  
• die Übernahme soll in der ersten Hälfte 2020 abgeschlossen werden
  

ir.achillion.com/news-releases/...ls/alexion-acquire-achillion

www.thestreet.com/markets/...ls-to-acquire-achillion-15128211

Achillion Aktionäre geben grünes Licht für die Übernahme durch Alexion

"Under the terms of the agreement, which was announced on October 16, 2019, Alexion will acquire Achillion for an initial consideration of approximately $930 million, or $6.30 per share in cash for each share of Achillion common stock. The transaction includes the potential for additional consideration in the form of non-tradeable contingent value rights (CVRs), which will be paid to Achillion shareholders if certain clinical and regulatory milestones are achieved within specified periods. These include $1.00 per share for the U.S. FDA approval of danicopan and $1.00 per share for ACH-5228 Phase 3 initiation."

ir.achillion.com/news-releases/...greement-be-acquired-alexion

U.S Handelskommission gibt grünes Licht

www.sec.gov/Archives/edgar/data/1070336/...330/d871768d8k.htm

letzter Kurs

www.pharmaceutical-business-review.com/news/alexion-achillion/

• Danicopan =ALXN2040
  
• ACH-5228 = ALNX2050
  

www.fiercebiotech.com/biotech/...am-after-seeing-phase-2-data